论文部分内容阅读
作者在147例活检证实的胃肠道、乳腺、肺和其他恶性肿癌的病人中,进行血浆癌胚胎抗原(CEA)和磷酸己糖同功酶(PHI)、r-谷酰胺转肽酶(r-GTP)和乳酸脱氢酶(LDH)的测定。将病人分成(1)有肝转移的,(2)无肝转移的和(3)临床治愈且无肝疾病,化验肝功能无异常者。结果(1)(2)两组 CEA 和三个酶均比(3)组高,而(1)组最高。有肝转移的78%的胃肠道癌及85%的肺癌可仅用 CEA 一项测定即可发现而60%乳腺癌、92%肺癌和41%其他癌需 CEA 连同一种或多种酶的测定始能发现。CEA 和酶的增高反映肿癌扩散的广度。CEA 和 PHI 的量最高者,常常是辨识病人有肝转移的最好指标。在胃肠道癌病人这两类试验起互相辅助作用,但肝脏
The authors performed plasma carcinoembryonic antigen (CEA), phosphohexose isozyme (PHI), and r-glutamyl transpeptidase in 147 patients with biopsy-proven gastrointestinal, breast, lung, and other malignant tumours. Determination of r-GTP) and lactate dehydrogenase (LDH). The patients were divided into (1) liver metastases, (2) liver metastases, (3) clinical cures and no liver disease, and no abnormal liver function tests. Results (1) (2) CEA and three enzymes in both groups were higher than those in group (3), while those in group (1) were highest. 78% of gastrointestinal cancers with liver metastases and 85% of lung cancers can be detected with CEA alone and 60% breast cancer, 92% lung cancer, and 41% other cancers require CEA together with one or more enzymes Measurements can only be found. Increases in CEA and enzymes reflect the breadth of tumor spread. The highest amounts of CEA and PHI are often the best indicators to identify patients with liver metastases. The two types of tests in gastrointestinal cancer patients play a complementary role, but the liver